Sohn Catherine A.

Director Sohn sold 29,413 shares (entire position) for $1,149,054.36 across 2 transactions; stock up 42.0% in 90 days

Catherine A. Sohn executed 2 separate sales totaling 29,413 shares for $1,149,054.36, divesting her entire position at a blended average price of $39.07 per share on January 6-7, 2026. The stock has appreciated 42.0% over the prior 90 days and currently trades at $38.95, near the top of its 52-week range. Sohn's cross-ticker track record shows 100% win rate on her prior 90-day holds, though with only 2 prior buys, suggesting limited historical data at this specific ticker. Given that Maze is pre-revenue and reporting quarterly net losses of $-30,087,000, the complete liquidation of a director's holdings may merit observation of regulatory filings and company disclosures.

Director Catherine A. Sohn bought 500 shares of Altimmune at $4.24; stock down 22% in 30 days, but director held winning prior trade.

Director Catherine A. Sohn purchased 500 shares at $4.24 on 2026-01-05, increasing her stake by 50.0% from 1,000 to 1,500 shares. The stock is currently trading at $4.09, down 22.0% over the past 30 days and 47.0% below its 52-week high of $7.71. Notably, Sohn's prior buy at this ticker (on 2025-03-17) generated a 90-day return of +19.6%, demonstrating successful timing on that occasion. The company faces material headwinds: revenue declined 95.3% year-over-year to $5.0K in the latest quarter, and the firm reported a net loss of $-19.0M over its most recent full fiscal year. A cluster of 3 other insiders also purchased shares within the past 14 days, suggesting coordinated confidence at current valuations despite the deteriorated revenue environment.

Director Sohn Catherine A. buys 1,000 shares of ALT at $5.78 as stock down -48.6% from 52-week high

Director Catherine A. Sohn purchased 1,000 shares at $5.78, establishing an initial position in Altimmune. The purchase occurred as the stock trades 48.6% below its 52-week high of $10.91 and has declined 29.0% over the prior 90 days. The company reported a net loss of $-22.8M in its most recent period against revenue of $5.0K, reflecting substantial operating losses and a -95.3% decline in annual revenue growth. This first-time insider purchase by a director in a deeply unprofitable biotech occurs in a context of significant downward price momentum and operational distress, presenting a mixed signal absent clarity on forward catalysts or the rationale behind the entry price relative to recent trading levels.